|The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Results from a phase 2 study of atezolizumab plus bevacizumab in women with advanced cervical cancer who had received prior treatment with bevacizumab showed only modest clinical benefit associated with a short median progression-free survival (PFS). The findings from this study were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.
Because clinical studies have shown relatively low response rates to single-agent immune checkpoint inhibitors in advanced cervical cancer, combination therapy with atezolizumab, an antibody against programmed cell death ligand-1 (PD-L1), and bevacizumab was investigated in the setting. This approach was based on previous evidence showing improved T-cell infiltration into tumor with therapies targeting vascular epithelial growth factor in combination with PD-L1 blockade.
Ten of the 11 patients with recurrent, persistent, or metastatic cervical cancer enrolled in the study (ClinicalTrials.gov Identifier: NCT02921269) were evaluable for response. Among these 10 patients, 2 had an unconfirmed partial response and 5 had stable disease as their best response, with progressive disease observed in 3 patients. Median PFS and median overall survival (OS) were 2.9 months and 9 months, respectively.
Grade 3/4 adverse events occurred in 73% of patients. Treatment-related grade 3/4 adverse events were reported in 27% of patients, and included thrombosis and hemorrhage due to bevacizumab, and arachnoiditis, sensorineural hearing loss, and lower extremity weakness due to atezolizumab.
As a result of these findings, the authors concluded that “the trial will not expand to the second stage.”
Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.
- Friedman CF, Snyder A, Sharon E, et al. A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer. Presented at: The Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 34.